The interim data shows a +8.9-letter improvement in best-corrected visual acuity (BCVA) and a 68-micron reduction in central subfield thickness (CST) for DURAVYU 2.7mg. How significant is this early and sustained response for DME patients, and what does it suggest about DURAVYU’s mechanism of action?

DURAVYU demonstrated visual and anatomical improvements over the aflibercept control. In your opinion, how does this compare to other anti-VEGF therapies, and what advantages does DURAVYU’s sustained delivery provide?

At the 16-week mark, 82% of eyes in the DURAVYU 2.7mg arm were supplement-free, compared to 50% in the aflibercept control group. How does this reduction in treatment burden impact patients’ quality of life, and could it address current gaps in DME care?

No DURAVYU-related ocular or systemic serious adverse events have been reported, and issues such as endophthalmitis and intraocular inflammation were absent. What does this favorable safety profile indicate about DURAVYU’s long-term suitability for DME management?

The data highlights that DURAVYU showed visual and anatomical improvements as early as Week 4. How important is this rapid bioavailability for patients with DME, and could it help in cases where immediate symptom relief is critical?

The positive trend in both BCVA and CST has continued in patients reaching the 24-week visit. Based on these interim results, what are your expectations for DURAVYU’s long-term efficacy and durability in managing DME?

Given that DURAVYU is also being tested in pivotal Phase 3 trials for wet AMD, do you believe there could be crossover benefits or insights from these trials that might apply to DME treatment?

With full topline data anticipated in early 2025, what potential impact do you foresee for DURAVYU in the broader market of retinal disease treatments, particularly for patients needing a durable, low-burden option for DME?